NICE’s Approval of Marstacimab for Hemoph...

By João L. Carapinha

May 30, 2025

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending marstacimab hemophilia B (Hympavzi®), a novel subcutaneous monoclonal antibody, for prophylaxis in severe hemophilia B but not for hemophilia...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.